🔷 Zydus Lifesciences Incorporates US-Based Subsidiary to Strengthen Biologics Footprint

New Entity Zylidac Bio LLC Set to Acquire Agenus Manufacturing Assets in California **Mumbai, July 12, 2025:** Zydus Lifesciences Ltd. (BSE: 532321 | NSE: ZYDUSLIFE) has announced the incorporation of its new **wholly owned US-based subsidiary, Zylidac Bio LLC**, as part of its strategic expansion into the biologics manufacturing space. The move aligns with Zydus’ long-term global growth vision in specialty pharmaceuticals and advanced therapies. Zylidac Bio LLC, incorporated on **July 11, 2025**, will serve as the acquiring entity for the previously announced deal involving **two state-of-the-art biologics facilities in Emeryville and Berkeley, California**, currently owned by **Agenus West LLC and Agenus Inc.**. These facilities will significantly bolster Zydus’ manufacturing capabilities in biologics, a segment witnessing rapid global demand. The company clarified that Zylidac Bio LLC has been incorporated without initial share capital, consistent with US LLC structures. As a wholly owned arm of **Zydus Pharmaceuticals USA Inc.**, Zylidac Bio is classified as a related party within the Group but involves no additional promoter interests. With this step, Zydus reaffirms its commitment to deepening its presence in **high-value biologics** and expanding its manufacturing footprint in the key US market. 📄 **Source:** Exchange Filing | **Disclaimer:** For informational purposes only.